###begin article-title 0
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF</italic>
###xml 6 11 6 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 15 22 15 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: Primary or secondary genetic events in colorectal carcinogenesis?
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF</italic>
###xml 6 11 6 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 15 22 15 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 105 110 105 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 114 121 114 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 132 137 132 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 227 232 227 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1 </italic>
###xml 321 325 321 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 327 332 327 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 336 343 336 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 479 484 479 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1 </italic>
BRAF, KRAS and PIK3CA mutations are frequently found in sporadic colorectal cancer (CRC). In contrast to KRAS and PIK3CA mutations, BRAF mutations are associated with tumours harbouring CpG Island methylation phenotype (CIMP), MLH1 methylation and microsatellite instability (MSI). We aimed at determine the frequency of KRAS, BRAF and PIK3CA mutations in the process of colorectal tumourigenesis using a series of colorectal polyps and carcinomas. In the series of polyps CIMP, MLH1 methylation and MSI were also studied.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 101 106 101 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1 </italic>
Mutation analyses were performed by PCR/sequencing. Bisulfite treated DNA was used to study CIMP and MLH1 methylation. MSI was detected by pentaplex PCR and Genescan analysis of quasimonomorphic mononucleotide repeats. Chi Square test and Fisher's Exact test were used to perform association studies.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 6 13 6 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 16 21 16 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 73 78 73 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 112 119 112 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 157 162 157 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 309 313 309 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF</italic>
###xml 315 320 315 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1 </italic>
###xml 516 521 516 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 525 532 525 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 573 578 573 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 710 712 710 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 810 812 810 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
KRAS, PIK3CA or BRAF occur in 71% of polyps and were mutually exclusive. KRAS mutations occur in 35% of polyps. PIK3CA was found in one of the polyps. V600E BRAF mutations occur in 29% of cases, all of them classified as serrated adenoma. CIMP phenotype occurred in 25% of the polyps and all were mutated for BRAF. MLH1 methylation was not detected and all the polyps were microsatellite stable. The comparison between the frequency of oncogenic mutations in polyps and CRC (MSI and MSS) lead us to demonstrate that KRAS and PIK3CA are likely to precede both types of CRC. BRAF mutations are likely to precede MSI carcinomas since the frequency found in serrated polyps is similar to what is found in MSI CRC (P = 0.9112), but statistically different from what is found in microsatellite stable (MSS) tumours (P = 0.0191).
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 22 26 22 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF</italic>
###xml 28 33 28 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 37 44 37 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 220 225 220 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 391 396 391 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 434 439 434 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 498 503 498 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 520 525 520 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
Our results show that BRAF, KRAS and PIK3CA mutations occur prior to malignant transformation demonstrating that these oncogenic alterations are primary genetic events in colorectal carcinogenesis. Further, we show that BRAF mutations occur in association with CIMP phenotype in colorectal serrated polyps and verified that colorectal serrated polyps and MSI CRC show a similar frequency of BRAF mutations. These results support that BRAF mutations harbour a mild oncogenic effect in comparison to KRAS and suggest that BRAF mutant colorectal cells need to accumulate extra epigenetic alterations in order to acquire full transformation and evolve to MSI CRC.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 185 186 185 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 433 437 433 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 439 446 439 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 450 455 450 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
In microsatellite unstable (MSI) colorectal tumours, both sporadic and inherited forms, hundreds of thousands of mutations accumulate within repetitive sequences throughout the genome [1]. Although genes with repetitive sequences are clear targets in tumours with a defective mismatch repair system, mutations in non-repetitive sequences are also found in MSI tumours. An example of this is the occurrence of activating mutations of KRAS, PIK3CA and BRAF genes.
###end p 11
###begin p 12
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 33 38 33 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 96 101 96 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 180 181 180 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 182 183 182 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 224 229 224 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1 </italic>
###xml 256 257 256 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 311 312 311 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 350 355 350 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 436 437 436 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 440 445 440 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 489 490 489 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 491 492 491 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 493 494 493 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 544 545 544 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 546 547 546 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 579 584 579 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 632 637 632 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1 </italic>
###xml 664 665 664 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 697 698 697 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 701 708 701 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 760 761 760 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 787 794 787 794 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 844 845 844 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 846 848 846 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 894 901 894 901 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 951 953 951 953 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 974 981 974 981 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 1051 1055 1051 1055 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 1056 1061 1056 1061 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 1101 1103 1101 1103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1151 1158 1151 1158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 1180 1185 1180 1185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1 </italic>
Activating mutations of BRAF and KRAS are frequently found in sporadic colorectal (CRC) cancer. BRAF mutations occur in about 10 to 18% of CRC overall and in 30 to 45% of MSI CRC [2,3], more frequently in tumours harbouring MLH1 promoter hypermethylation [3] and with a CpG island methylation phenotype (CIMP) [4]. In microsatellite stable (MSS) CRC BRAF mutations are rare and whenever present are associated with advanced carcinomas [5]. KRAS mutations occur in both MSI (in about 20%) [3,6,7] and MSS (in about 35%) subsets of sporadic CRC [5,6]. Within the MSI subset of CRC KRAS mutations do not associate with the presence of MLH1 promoter hypermethylation [3] or with the presence of CIMP [8]. PIK3CA mutations were identified in various tumour models [9]. In colorectal tumours, PIK3CA mutations are present in 14% to 25% of the cases [9,10] and no differences in frequency and type of PIK3CA mutations were found between MSI and MSS subsets [10]. Further, whenever PIK3CA mutations occur in CRC they can occur in concomitance with activating KRAS-BRAF mutations, both in MSI and MSS tumours [10]. Nothing is known on the relationship between PIK3CA mutations and CIMP or MLH1 methylation in colorectal carcinomas.
###end p 12
###begin p 13
###xml 74 78 74 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 80 85 80 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 89 96 89 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 224 229 224 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1 </italic>
###xml 432 436 432 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 438 443 438 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 447 454 447 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
The aim of the present study was to determine the timing of occurrence of KRAS, BRAF and PIK3CA mutations in the process of colorectal tumourigenesis and study the association of these mutational oncogenic events with CIMP, MLH1 methylation and MSI phenotype. In order to achieve our goal we evaluated the frequency and type of these epi/genetic events in a series of 17 colorectal polyps. Furthermore, we compared the frequency of KRAS, BRAF and PIK3CA mutations found in polyps with the frequency found in a series of 103 sporadic colorectal tumours, 50 MSI CRC and 53 MSS CRC, in order to understand the importance of these oncogenic events for the progression of the various types of colorectal cancer.
###end p 13
###begin p 14
###xml 50 54 50 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF</italic>
###xml 56 61 56 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 65 72 65 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 243 248 243 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 335 340 335 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 394 399 394 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 458 463 458 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 480 485 480 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
In conclusion, our results show that mutations of BRAF, KRAS and PIK3CA occur in non-malignant lesions of colorectum demonstrating that these oncogenic alterations are primary genetic events in colorectal carcinogenesis. Further, we show that BRAF mutations occur in association with CIMP phenotype in colorectal serrated polyps while KRAS mutations are found alone. These results support that BRAF mutations harbour a mild oncogenic effect in comparison to KRAS and suggest that BRAF mutant colorectal cells need to accumulate extra epigenetic alterations in order to acquire full transformation.
###end p 14
###begin title 15
Methods
###end title 15
###begin p 16
###xml 398 400 398 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 507 508 507 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 675 680 675 680 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 694 699 694 699 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 1039 1040 1039 1040 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1176 1181 1172 1177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1 </italic>
###xml 1730 1734 1726 1730 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 1736 1743 1732 1739 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 1747 1752 1743 1748 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 1861 1862 1857 1858 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 522 530 <span type="species:ncbi:9606">patients</span>
Representative blocks of 17 colorectal polyps and 103 colorectal carcinomas formalin-fixed, paraffin embedded were retrieved from the Department of Pathology of the Hospital S. Joao. This study was a retrospective analysis and is in compliance with Helsinki declaration . The 103 sporadic CRC were previously classified for microsatellite status, 53 were MSS and 50 were MSI colorectal carcinomas [10]. The histological classification of the seventeen paraffin embedded colorectal polyps is listed in table 1. None of the patients included in this study had a positive family history. DNA from these 17 polyps was extracted using the Invisorb Spin Tissue Mini Kit (Invitek). BRAF (exon 15) and KRAS (exon 1) were amplified by PCR and the presence of mutations was detected by direct sequencing. To perform methylation studies, DNA extracted from paraffin embedded lesions was submitted to bisulfite treatment. CIMP was determined in 12 cases by methylation specific PCR (MSP) using the new panel of five markers described by Weisenberger [4]. The polyps were classified as CIMP (>/= 3 methylated markers), and CIMP-negative (</= 2 methylated markers). We were able to analyze MLH1 methylation in 7 samples. For that the promoter region of the gene was amplified using a set of CpG island flanking primers (sense 5'ttttgtttttattggttggatattt, antisense 5'ccttcaaccaatcacctcaatacct) followed by direct sequencing. Microsatellite instability studies were performed by genescan analyses of a PCR amplified panel of five mononucleotide markers (NR27, NR24, NR21, Bat25 and Bat26) using the Multiplex PCR Kit (Qiagen). MSI was considered when two or more microsatellite markers were altered. Association studies between the frequency of KRAS, PIK3CA and BRAF in colorectal polyps and MSI and MSS CRC were performed using the Chi Square test and Fisher's Exact test. A P-value </= 0.05 was considered to be statistically significant.
###end p 16
###begin p 17
Summary of the molecular and histological features of the colorectal polyps analyzed
###end p 17
###begin p 18
UnMet - unmethylated; nd - not determined; MHA - Mixed hyperplastic and adenomatous; HP - Hyperplastic polyp; SA - Serrated adenoma
###end p 18
###begin title 19
Results
###end title 19
###begin title 20
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 6 12 6 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA</italic>
###xml 18 23 18 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
KRAS, PIK3CA, and BRAF mutations occur prior to malignant transformation
###end title 20
###begin p 21
###xml 63 67 63 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 69 76 69 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 79 84 79 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 189 193 189 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 195 202 195 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 205 210 205 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 265 266 265 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
In our series of colorectal polyps, we found that mutations in KRAS, PIK3CA or BRAF are mutually exclusive and occur in the majority of these pre-malignant colorectal lesions. Mutations in KRAS, PIK3CA or BRAF occur in 12 (70.6%) of the 17 colorectal polyps (Table 1).
###end p 21
###begin p 22
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 53 58 53 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 256 261 256 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
KRAS mutations were found in 35.3% (6/17) of polyps. KRAS mutant polyps showed three different types of mutations with the same frequency within the two most common hotspot codons (12 and 13): G12D (33.3% - 2/6), G12V (33.3% - 2/6) and G13D (33.3% - 2/6). KRAS mutations were only found in polyps with some areas with dysplasia.
###end p 22
###begin p 23
###xml 39 44 39 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 75 82 75 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 155 156 155 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 163 170 163 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 299 306 299 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 417 419 417 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
In contrast with the high frequency of KRAS mutations found in our series, PIK3CA mutations were observed in only one of the polyps analyzed (5.9%) (Table 1). The PIK3CA mutation found was localized to exon 20 and affects amino acid 1023 leading to an arginine-glutamine substitution (R1023Q). This PIK3CA mutation resides in a hotspot exon for mutations that has been previously reported in a MSI colorectal tumour [10].
###end p 23
###begin p 24
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 62 63 62 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 70 75 70 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 143 148 143 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 174 179 174 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
BRAF mutations were found in 29.4% (5/17) of the cases (Table 1). All BRAF mutations found in our series of polyps corresponded to the hotspot BRAF V600E and all polyps with BRAF mutations exhibited the serrated architecture.
###end p 24
###begin title 25
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
BRAF mutations occur in association with CIMP phenotype in colorectal polyps
###end title 25
###begin p 26
###xml 43 48 43 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1 </italic>
###xml 130 134 130 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 136 141 136 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 145 152 145 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
We studied the presence of CIMP phenotype, MLH1 promoter methylation and MSI phenotype and their association with the presence of KRAS, BRAF and PIK3CA mutations in the series of polyps.
###end p 26
###begin p 27
###xml 24 25 24 25 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 175 180 173 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 187 188 185 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 223 228 221 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
Using the Weisenberger [4] panel of CIMP markers three of 12 polyps analyzed (25%) were classified as CIMP (>/= 3 methylated markers). All of the CIMP polyps were mutated for BRAF (Table 1). None of the CIMP polyps harbour KRAS mutations.
###end p 27
###begin p 28
###xml 28 33 28 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1 </italic>
###xml 108 112 108 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 126 131 126 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 255 260 255 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1 </italic>
###xml 267 268 267 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 378 380 378 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
The methylation analysis of MLH1 was possible in 7 of the 17 polyps. Two of these 7 polyps were mutated for KRAS, 2 harboured BRAF mutations and 3 were wild-type for both genes. None of the 7 polyps studied harboured methylation in the promoter region of MLH1 (Table 1). Furthermore, we determined the MSI status of all polyps using the pentaplex set of microsatellite markers [11]. None of them were MSI.
###end p 28
###begin title 29
Colorectal serrated polyps and MSI CRC show a similar frequency of BRAF mutations
###end title 29
###begin p 30
###xml 41 45 41 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 47 54 47 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 58 63 58 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 249 250 249 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
In order to understand the importance of KRAS, PIK3CA and BRAF mutations for the progression of the various types of colorectal cancer, we compared the frequency of these oncogenic events in the series of polyps and in 50 MSI and 53 MSS CRC (Figure 1).
###end p 30
###begin p 31
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 6 13 6 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 17 22 17 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 0 77 0 77 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>KRAS</italic>, <italic>PIK3CA </italic>and <italic>BRAF </italic>mutation frequencies between MSI/MSS CRC and CR polyps.</bold>
###xml 95 99 95 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 101 108 101 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 112 117 112 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 199 201 199 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
KRAS, PIK3CA and BRAF mutation frequencies between MSI/MSS CRC and CR polyps. The frequency of KRAS, PIK3CA and BRAF mutations in MSI and MSS CRC was based on previous results of our group in Velho [10]. In brackets is represented the total of cases that were analyzed for each gene.
###end p 31
###begin p 32
###xml 85 90 85 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 118 123 118 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 239 241 239 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 254 256 254 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Ten of the 50 (20%) MSI and 21 of the 53 (39.6%) MSS colorectal carcinomas exhibited KRAS mutations. The frequency of KRAS mutations found in the MSI and MSS CRC was not statistical different from the frequency found in colorectal polyps (P = 0.2014 and P = 0.7497, respectively).
###end p 32
###begin p 33
###xml 26 33 26 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 86 93 86 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 302 304 302 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 348 350 348 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
The same was observed for PIK3CA mutations. MSI and MSS colorectal carcinomas harbour PIK3CA in 8 of the 50 (16%) and in 6 of the 53 (11.3%) cases, respectively. The frequency of mutations found in polyps, although lower in comparison to colorectal carcinomas, is not statistically different from MSI (P = 0.4296 - Fisher's Exact P-Value) and MSS (P > 0.9999 - Fisher's Exact P-Value) colorectal carcinomas.
###end p 33
###begin p 34
###xml 28 33 28 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 148 153 148 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 245 250 245 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 261 263 261 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 304 309 304 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 387 389 387 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Concerning the frequency of BRAF alterations in colorectal carcinomas, 14 of the 50 (28%) MSI and 4 of the 53 (7.5%) in MSS colorectal tumours show BRAF mutations. We found that MSI CRC and colorectal serrated polyps show a similar frequency of BRAF mutations (P = 0.9112). In contrast, the frequency of BRAF mutations in MSS carcinomas and colorectal polyps is significantly different (P = 0.0191).
###end p 34
###begin title 35
Discussion
###end title 35
###begin p 36
###xml 177 182 177 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 191 198 191 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 208 213 208 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 238 243 238 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 422 424 422 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 439 441 439 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 456 461 456 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 578 583 578 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 710 715 710 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 842 843 842 843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 886 891 886 891 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 960 962 960 962 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 963 965 963 965 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1057 1059 1057 1059 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
Distinct types of colorectal polyps represent pre-malignant lesions of the intestinal tract. In our series of colorectal polyps we found the majority (71%) harbour mutations in KRAS (35.3%), PIK3CA (5.9%) or BRAF (29.4%) genes. Regarding KRAS mutations we show that these mutations occur in cases of hyperplasic polyps and in hyperplastic polyps with some areas of dysplasia in accordance to the recent reports of Wynter [12] and O'Brien [13] showing that KRAS mutations occur in pre-malignant lesions of the colorectum other than pure adenomas. When comparing the frequency of KRAS mutations found in our series of colorectal polyps with those observed within the MSS and MSI subsets of CRC, the frequency of KRAS mutations found in polyps is not statistically different from the frequency observed in MSI and MSS colorectal tumours (Figure 1). Both observations highlight the role of KRAS activation in the initiation of the different types of sporadic CRC [12-14] besides its role in the adenoma-carcinoma multistep pathway of colorectal carcinogenesis [15].
###end p 36
###begin p 37
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 270 272 270 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 367 374 367 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 433 438 433 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 442 447 442 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 486 493 486 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 546 551 546 551 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 555 560 555 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
PIK3CA mutations were found in only one of the polyps (6%) but this frequency is not significantly different from what is observed in CRC independently of MSI status. The mutation found in our series of colorectal polyps was previously described in a colorectal tumour [10] suggesting that it harbours a pathogenic effect. Further, it is interesting to note that the PIK3CA alteration found in the single affected polyp is wild-type KRAS and BRAF case. This result suggests that mutant PIK3CA is likely to be an alternative rare genetic event to KRAS and BRAF in pre-malignant lesions of the colon.
###end p 37
###begin p 38
###xml 17 22 17 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 165 170 165 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 361 366 361 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 563 568 563 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 571 581 571 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ink4a/Arf </italic>
###xml 606 608 606 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 648 653 648 653 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 802 804 802 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 805 807 805 807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 330 334 <span type="species:ncbi:10090">mice</span>
###xml 517 521 <span type="species:ncbi:10090">mice</span>
###xml 789 794 <span type="species:ncbi:9606">human</span>
The frequency of BRAF mutations in polyps (30%) is higher than the frequency observed in overall CRC (17%). This observation lead us to speculate that a fraction of BRAF mutant polyps do not progress to carcinoma and remain as non-malignant colorectal lesions as an endpoint stage. In accordance with this, it was demonstrated in mice that expression of active BRAF in the lungs lead to an initial burst of cell proliferation followed by growth arrest rarely inducing spontaneous progression to adenocarcinoma unless mice were deliberately engineered to lack the TP53 or Ink4a/Arf tumour suppressor genes [16]. This study and our data suggest that BRAF may need to cooperate with other factors (genetic or epigenetic) to progress to colorectal carcinoma, as it was previously proposed for human naevi [17,18].
###end p 38
###begin p 39
###xml 29 34 29 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 120 122 120 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 178 183 178 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 352 357 352 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 438 443 438 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 528 530 528 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 531 533 531 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 554 556 554 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 557 559 557 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 560 562 560 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 563 565 563 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
Noteworthy, the frequency of BRAF mutations in colorectal polyps is similar to the frequency observed in MSI CRC (28%) (P = 0.9112). These data raises the hypothesis that mutant BRAF triggers a distinct pathway of colorectal carcinogenesis leading to the formation of MSI colorectal tumours different from the adenoma-carcinoma sequence. Interestingly BRAF mutations occurred only in polyps with the serrated architecture supporting that BRAF activation is pivotal in the serrated pathway of CRC as advanced previously by Jass [19,20] and other authors [13,14,21,22].
###end p 39
###begin p 40
###xml 142 144 142 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 145 147 145 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 168 173 168 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 303 308 303 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 434 436 434 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 437 439 437 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 461 466 461 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 595 600 595 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 659 664 659 664 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 676 681 676 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
Analyzing the frequency of CIMP in colorectal polyps we have demonstrated that the results obtained are similar to what was described in CRC [13,14,20,22] showing that BRAF mutations are associated with CIMP phenotype in the initial steps of carcinogenesis before malignant transformation. In contrast, KRAS mutations were only associated to with low levels of methylation as it was previously observed in primary colorectal tumours [19,23], demonstrating that KRAS mutations are associated to mild effects in the methylation profile during colorectal carcinogenesis. These results support that BRAF mutations harbour a mild oncogenic effect in comparison to KRAS and suggest BRAF mutant colorectal cells need to accumulate extra epigenetic alterations in order to acquire full transformation.
###end p 40
###begin p 41
###xml 99 104 99 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 158 159 158 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 160 161 160 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 219 224 219 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1 </italic>
###xml 439 441 439 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 462 467 462 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 535 537 535 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 564 569 564 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1 </italic>
MSI and loss of expression of MLH1 due to promoter hypermethylation are frequently associated with BRAF mutation and CIMP in MSI sporadic colorectal tumours [2-4]. In our series of colorectal polyps we did not detected MLH1 promoter hypermethylation which is in agreement with the fact that none of the analyzed polyps harboured MSI. Our data is in agreement with the results previously described in serrated adenomas described by Sawyer [24] demonstrating that BRAF and CIMP precedes MSI as proposed by the model advanced by O'Brien [14]. The late acquisition of MLH1 methylation leading to the accumulation of mutations throughout the genome targeting important genes (tumour suppressor genes or proto-oncogenes) involved in the control of cellular homeostasis may bridge the transition from a pre-malignant to a malignant lesion.
###end p 41
###begin title 42
Conclusion
###end title 42
###begin p 43
###xml 50 55 50 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 59 66 59 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 339 344 339 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 431 436 431 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 557 562 557 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 600 605 600 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 664 669 664 669 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 686 691 686 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
In conclusion, our results show that mutations of KRAS and PIK3CA occur in non-malignant lesions of colorectum and the frequency of these mutations is not distinct in polyps and MSS and MSI CRC demonstrating that these oncogenic alterations are primary genetic events in the two subsets of colorectal carcinogenesis. Further, we show that BRAF mutations occur in association with CIMP phenotype in colorectal serrated polyps while KRAS mutations are found alone. Further we show that only MSI CRC and colorectal serrated polyps harbour similar frequency of BRAF mutations. These results support that BRAF mutations harbour a mild oncogenic effect in comparison to KRAS and suggest that BRAF mutant colorectal cells need to accumulate extra epigenetic alterations in order to acquire full transformation and evolve to MSI CRC.
###end p 43
###begin title 44
Competing interests
###end title 44
###begin p 45
The authors declare that they have no competing interests.
###end p 45
###begin title 46
Authors' contributions
###end title 46
###begin p 47
###xml 7 12 7 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 16 23 16 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 136 141 136 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 385 390 385 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 201 208 <span type="species:ncbi:9606">patient</span>
SV did BRAF and PIK3CA mutation screening, performed methylation studies (CIMP and MLH1 methylation) and drafted the manuscript. CM did KRAS mutation screening. LC performed MSI analyses. CA collected patient material with distinct subtypes of colorectal polyps. RH analyzed the MSI status of CRC. FS and FC were responsible for the histological classification of CRC. CO did BRAF and KRAS screening in CRC and helped to draft the manuscript. RS conceived and designed the study, analyzed the results and helped to draft the manuscript. All authors read and approved the final manuscript.
###end p 47
###begin title 48
Pre-publication history
###end title 48
###begin p 49
The pre-publication history for this paper can be accessed here:
###end p 49
###begin p 50

###end p 50
###begin title 51
Acknowledgements
###end title 51
###begin p 52
To the FCT grant POCTI/SAU-OBS/56921/2004 and PTDC/SAU-OBD/68310/2006
###end p 52
###begin article-title 53
Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis
###end article-title 53
###begin article-title 54
BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors
###end article-title 54
###begin article-title 55
Activated BRAF targets proximal colon tumors with mismatch repair deficiency and MLH1 inactivation
###end article-title 55
###begin article-title 56
CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer
###end article-title 56
###begin article-title 57
KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression
###end article-title 57
###begin article-title 58
Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status
###end article-title 58
###begin article-title 59
BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency
###end article-title 59
###begin article-title 60
Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer
###end article-title 60
###begin article-title 61
###xml 50 55 <span type="species:ncbi:9606">human</span>
High frequency of mutations of the PIK3CA gene in human cancers
###end article-title 61
###begin article-title 62
The prevalence of PIK3CA mutations in gastric and colon cancer
###end article-title 62
###begin article-title 63
Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR
###end article-title 63
###begin article-title 64
Methylation patterns define two types of hyperplastic polyp associated with colorectal cancer
###end article-title 64
###begin article-title 65
Hyperplastic and serrated polyps of the colorectum
###end article-title 65
###begin article-title 66
Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points
###end article-title 66
###begin article-title 67
Genetic alterations during colorectal-tumor development
###end article-title 67
###begin article-title 68
###xml 6 11 <span type="species:ncbi:10090">mouse</span>
A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors
###end article-title 68
###begin article-title 69
Oncogenic BRAF Induces Senescence and Apoptosis through Pathways Mediated by the Secreted Protein IGFBP7
###end article-title 69
###begin article-title 70
###xml 57 62 <span type="species:ncbi:9606">human</span>
BRAFE600-associated senescence-like cell cycle arrest of human naevi
###end article-title 70
###begin article-title 71
Classification of colorectal cancer based on correlation of clinical, morphological and molecular features
###end article-title 71
###begin article-title 72
Colorectal cancer: a multipathway disease
###end article-title 72
###begin article-title 73
Role of BRAF-V600E in the serrated pathway of colorectal tumourigenesis
###end article-title 73
###begin article-title 74
BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum
###end article-title 74
###begin article-title 75
Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer
###end article-title 75
###begin article-title 76
Molecular characteristics of serrated adenomas of the colorectum
###end article-title 76

